Contact
searchSearch
HMP Global
Login
Quiz

Vorasidenib for Previously Untreated Patients With Residual or Recurrent Grade 2 IDH-Mutant Glioma

08/19/2025

Related Content

News
Auceliciclib Demonstrates Favorable Safety and Preliminary Activity in Advanced Solid Tumors and Recurrent High-Grade Glioma
03/03/2026
Emily Estrada
Auceliciclib was well-tolerated and demonstrated preliminary disease control with promising safety among heavily pretreated patients with advanced solid tumors and recurrent high-grade glioma.
Auceliciclib was well-tolerated and demonstrated preliminary disease control with promising safety among heavily pretreated patients with advanced solid tumors and recurrent high-grade glioma.
Auceliciclib was well-tolerated...
03/03/2026
Oncology
Sameer Farouk Sait, MD, Memorial Sloan Kettering Cancer Center
Videos
MAPK Pathway-Guided Treatment for Pediatric Low-Grade Brainstem Glioma
02/23/2026
Sameer Farouk Sait, MBBS
Sameer Farouk Sait, MBBS, uses a pediatric patient case to illustrate MAPK pathway–driven treatment decision-making in focal low-grade brainstem glioma, highlighting the role of molecular profiling in guiding individualized therapy while...
Sameer Farouk Sait, MBBS, uses a pediatric patient case to illustrate MAPK pathway–driven treatment decision-making in focal low-grade brainstem glioma, highlighting the role of molecular profiling in guiding individualized therapy while...
Sameer Farouk Sait, MBBS, uses a...
02/23/2026
Oncology
News
¹⁸F-DOPA-PET Detects Early Treatment Response in IDH-Mutant Glioma
02/06/2026
Stephanie Holland
Results from a real-world imaging analysis suggest that ¹⁸F-DOPA-PET and advanced MRI sequences may provide earlier indicators of treatment response than conventional MRI in patients with IDH-mutant glioma receiving IDH inhibitors.
Results from a real-world imaging analysis suggest that ¹⁸F-DOPA-PET and advanced MRI sequences may provide earlier indicators of treatment response than conventional MRI in patients with IDH-mutant glioma receiving IDH inhibitors.
Results from a real-world...
02/06/2026
Radiopharmaceutical Education Institute
Diego Prost, MD
Videos
18F-DOPA-PET Detects Early Response in IDH-Mutant Glioma
02/03/2026
Diego Prost, MD
Diego Prost, MD, discusses findings from a real-world imaging analysis evaluating early response assessment in patients with IDH1/2-mutant glioma treated with IDH inhibitors.
Diego Prost, MD, discusses findings from a real-world imaging analysis evaluating early response assessment in patients with IDH1/2-mutant glioma treated with IDH inhibitors.
Diego Prost, MD, discusses...
02/03/2026
Radiopharmaceutical Education Institute

Recent News

News
Belantamab Mafodotin Plus Bortezomib and Dexamethasone in Relapsed/Refractory Multiple Myeloma
03/25/2026
Stephanie Holland
Results from arm B of the DREAMM-6 trial demonstrated that belantamab mafodotin plus bortezomib and dexamethasone shows strong clinical promise with manageable safety in relapsed/refractory multiple myeloma.
Results from arm B of the DREAMM-6 trial demonstrated that belantamab mafodotin plus bortezomib and dexamethasone shows strong clinical promise with manageable safety in relapsed/refractory multiple myeloma.
Results from arm B of the...
03/25/2026
Oncology
FDA Approval
FDA Grants Approval to Relacorilant Plus Nab-Paclitaxel for Platinum-Resistant Ovarian Cancer, Fallopian Tube, or Primary Peritoneal Cancer
03/25/2026
Emily Estrada
The FDA approved relacorilant in combination with nab-paclitaxel for adults with platinum-resistant epithelial ovarian, fallopian tube, or primary peritoneal cancer who have received 1 to 3 prior systemic therapies, including bevacizumab.
The FDA approved relacorilant in combination with nab-paclitaxel for adults with platinum-resistant epithelial ovarian, fallopian tube, or primary peritoneal cancer who have received 1 to 3 prior systemic therapies, including bevacizumab.
The FDA approved relacorilant in...
03/25/2026
Oncology
News
Imlunestrant Demonstrates Favorable Safety Alone and With Abemaciclib in Advanced Breast Cancer
03/24/2026
Emily Estrada
Detailed safety findings from the phase 3 EMBER-3 trial further support imlunestrant alone or in combination with abemaciclib in patients with ER-positive, HER2-negative advanced breast cancer.
Detailed safety findings from the phase 3 EMBER-3 trial further support imlunestrant alone or in combination with abemaciclib in patients with ER-positive, HER2-negative advanced breast cancer.
Detailed safety findings from...
03/24/2026
Oncology
News
Early Dose Reductions Improve Persistence With Adjuvant Abemaciclib in High-Risk Early Breast Cancer
03/24/2026
Emily Estrada
Real-world data from the US Flatiron Health Research Database demonstrate that most patients with HR-positive, HER2-negative early breast cancer remain on adjuvant abemaciclib at 6 months, with dosing strategies playing a critical role in...
Real-world data from the US Flatiron Health Research Database demonstrate that most patients with HR-positive, HER2-negative early breast cancer remain on adjuvant abemaciclib at 6 months, with dosing strategies playing a critical role in...
Real-world data from the US...
03/24/2026
Oncology
News
Clinical and Molecular Factors Influence Outcomes of Sevabertinib in HER2-Mutated NSCLC
03/24/2026
Stephanie Holland
Results from an exploratory analysis of the phase 1/2 SOHO-01 study suggest that clinical and molecular characteristics may influence treatment outcomes among patients with HER2-mutated non-small cell lung cancer receiving sevabertinib.
Results from an exploratory analysis of the phase 1/2 SOHO-01 study suggest that clinical and molecular characteristics may influence treatment outcomes among patients with HER2-mutated non-small cell lung cancer receiving sevabertinib.
Results from an exploratory...
03/24/2026
Oncology
News
Pharmacist-Led Interventions Improve Medication Management for Patients Receiving Vorasidenib for Low-Grade Gliomas
03/24/2026
Stephanie Holland
Results from a retrospective, single-center study suggest that pharmacist-led interventions play a critical role in optimizing medication management among patients with low-grade gliomas receiving vorasidenib.
Results from a retrospective, single-center study suggest that pharmacist-led interventions play a critical role in optimizing medication management among patients with low-grade gliomas receiving vorasidenib.
Results from a retrospective,...
03/24/2026
Oncology
FDA Approval
FDA Approves Nivolumab Plus Doxorubicin, Vinblastine, and Dacarbazine for Previously Untreated Patients With Advanced Classical Hodgkin Lymphoma
03/20/2026
Emily Estrada
Based on results from the SWOG 1826 trial, the FDA has approved nivolumab plus doxorubicin, vinblastine, and dacarbazine for previously untreated patients with advanced classical Hodgkin lymphoma.
Based on results from the SWOG 1826 trial, the FDA has approved nivolumab plus doxorubicin, vinblastine, and dacarbazine for previously untreated patients with advanced classical Hodgkin lymphoma.
Based on results from the SWOG...
03/20/2026
Oncology
News
Botensilimab Plus Balstilimab Demonstrates Promise in Refractory Metastatic Colorectal Cancer
03/18/2026
Emily Estrada
According to a comparative analysis of clinical trial data, botensilimab plus balstilimab provided a promising overall survival benefit in refractory MSS metastatic colorectal cancer.
According to a comparative analysis of clinical trial data, botensilimab plus balstilimab provided a promising overall survival benefit in refractory MSS metastatic colorectal cancer.
According to a comparative...
03/18/2026
Oncology
News
Belzutifan Plus Lenvatinib Improves PFS in Advanced Clear Cell Renal Cell Carcinoma
03/11/2026
Stephanie Holland
Interim results from the phase 3 LITESPARK-011 trial demonstrate that belzutifan plus lenvatinib significantly improved progression-free survival compared with cabozantinib among previously treated patients with advanced clear cell renal cell...
Interim results from the phase 3 LITESPARK-011 trial demonstrate that belzutifan plus lenvatinib significantly improved progression-free survival compared with cabozantinib among previously treated patients with advanced clear cell renal cell...
Interim results from the phase 3...
03/11/2026
Oncology
News
Mezigdomide Plus Carfilzomib and Dexamethasone Improves PFS in R/R Multiple Myeloma
03/11/2026
Stephanie Holland
Interim results from the phase 3 SUCCESSOR-2 trial demonstrate that mezigdomide plus carfilzomib and dexamethasone significantly improved PFS in patients with relapsed/refractory multiple myeloma versus carfilzomib and dexamethasone alone.
Interim results from the phase 3 SUCCESSOR-2 trial demonstrate that mezigdomide plus carfilzomib and dexamethasone significantly improved PFS in patients with relapsed/refractory multiple myeloma versus carfilzomib and dexamethasone alone.
Interim results from the phase 3...
03/11/2026
Oncology

HMP Global Products

Events

HMP Education Logo
HMP Omnimedia Logo
HMP Europe Logo
© 2026 HMP Global. All Rights Reserved.
Cookie Policy Privacy Policy Terms of Use